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Pulmonary embolism (PE) is potentially fatal and often requires emergency management. Because PE associated
with shock and/or hypotension carries a high risk of sudden death, emergency clinicians must rapidly make a
diagnosis and initiate appropriate therapeutic strategies, usually involving anticoagulant treatment. Traditional
anticoagulants, such as heparins and vitamin K antagonists, although effective and recommended by guidelines,
are associated with limitations. Several targeted, orally administered anticoagulants that may overcome some of
these constraints have been developed recently and undergone analysis in randomised, phase III clinical trials.
Rivaroxaban, a direct factor Xa inhibitor, was non-inferior to standard therapy with enoxaparin plus a vitamin K
antagonist for the prevention of recurrent, symptomatic venous thromboembolism (VTE) in patients with acute PE
and led to a 50% reduction in major bleeding. Dabigatran, a direct thrombin inhibitor, was also non-inferior to
standard therapy for the prevention of recurrent VTE or VTE-related death when given after a parenteral
anticoagulant and had a similar incidence of major bleeding. The results of a phase III study of apixaban, another
direct factor Xa inhibitor, for the acute treatment of VTE are expected in the near future. Rivaroxaban is now
approved in Europe and the US for the treatment of acute PE and prevention of recurrent VTE. This article reviews
the current guidance on the treatment of PE with special focus on the emergency setting, and considers data
regarding rivaroxaban and the other non-vitamin K antagonist oral anticoagulants and their potential role, including
patients who are and are not appropriate for treatment with these agents. Issues such as drug interactions, reversal
of anticoagulant effect and coagulation monitoring are also discussed.
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Pulmonary embolism (PE) is a potentially life-threatening
emergency. In approximately 80% of cases, PE results from
the embolisation of a deep venous thrombus [1,2]. Approxi-
mately 60% of patients with proven proximal deep vein
thrombosis (DVT) also show evidence of PE, and the ab-
sence of DVT in a patient with PE could indicate that the
fresh venous thrombus has already embolised [1,2]. Patients
with PE have case fatality rates of 7-11% owing to the acute
episode or a subsequent recurrence, which is higher than
that associated with proximal DVT [3].
The standard antithrombotic treatment for DVT and
PE is parenteral unfractionated heparin (UFH) or low* Correspondence: patrick.goldstein@chru-lille.fr
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in any medium, provided the original work is pmolecular weight heparin (LMWH, e.g. enoxaparin),
transitioning to an oral vitamin K antagonist (VKA) such
as warfarin. Fondaparinux is a parenteral alternative to
heparins. These agents are effective but have limitations,
some of which may be overcome by the more recently de-
veloped non-VKA oral anticoagulants (OACs) [4]. Based
on the phase III EINSTEIN trials, the direct factor Xa
inhibitor rivaroxaban is now approved in Europe and the
US for the treatment of DVT and PE as well as the pre-
vention of recurrent DVT and PE in adults [5,6]. In
addition, treatment studies involving the direct thrombin
inhibitor dabigatran have also been completed, and studies
of the direct factor Xa inhibitors apixaban and edoxaban
are ongoing. This review describes the current guidelines
for the treatment of patients with acute PE and considers
the potential role of non-VKA OACs in this paradigm.is an Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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Methods
Literature sources for this article were retrieved via
PubMed based on a series of searches using the names
of anticoagulant classes and specific generic names of
the agents discussed herein, in various combinations with
Boolean operators and the terms ‘deep vein thrombosis’,
‘pulmonary embolism’, ‘venous thromboembolism’ and
‘treatment’. Articles returned by these searches were
reviewed for relevance to the subject of this review, and the
reference lists of other pertinent review articles and guide-
lines documents were examined for additional sources
of information, such as congress abstracts.Current guidelines on the emergency treatment of
pulmonary embolism
The most recent international guidelines for the treatment
of venous thromboembolism (VTE) were released by the
American College of Chest Physicians (ACCP) in 2012 [7].
In Europe, the current European Society of Cardiology
(ESC) recommendations covering PE were issued in 2008
[3] and do not include non-VKA OACs.
Patients with a high likelihood of PE should immediately
receive effective anticoagulation, even pending the re-
sults of confirmatory diagnostic tests [3,7]. Severe or life-
threatening PE associated with shock and/or hypotension
should be treated with immediate intravenous UFH in
combination with thrombolytic therapy or, in the case of
contraindication or failure of thrombolysis, pulmonary
embolectomy with concurrent haemodynamic and respira-
tory support (Table 1) [3,7]. If the thrombotic episode is
acute but not considered immediately life threatening, i.e.
suspected PE not associated with haemodynamic instability,
anticoagulant therapy should be given. Initial parenteralTable 1 Current guidelines for the initial treatment of acute P
Diagnosis Recommendation
High-risk PE (with hypotension
and/or cardiogenic shock)
Thrombolytic therapy (for patients who
Accompanied by immediate i.v. UFH
Non-high-risk PE, including
suspected PE
Initial parenteral anticoagulation or riva
LMWH or fondaparinux preferred over:
i.v. UFH
s.c. UFH
For patients at high risk of bleeding an
UFH with an aPTT target range of 1.5-2
Initial treatment with UFH, LMWH or fo
least 5 days, with concurrent VKA starte
Parenteral treatment to be discontinue
levels for at least 2 consecutive days
*ACCP guidelines only; no grade of recommendation or level of evidence specified.
thromboplastin time, ESC European Society of Cardiology, INR international normali
embolism, s.c. subcutaneous, UFH unfractionated heparin, VKA vitamin K antagonistanticoagulation (LMWH or fondaparinux rather than UFH)
or oral rivaroxaban are recommended (Table 1) [7]. When
a parenteral agent is used initially, a VKA should be started
concurrently and the parenteral agent discontinued after a
minimum of 5 days’ treatment or when the international
normalised ratio (INR) stabilises within the target range of
2.0-3.0 for 2 consecutive days [3,7]. In contrast, rivaroxaban
is given alone at a dose of 15 mg twice daily for 3 weeks
followed by 20 mg once daily for the remainder of
treatment [5,6].Established anticoagulants for the treatment of
pulmonary embolism
UFH, given either subcutaneously or intravenously, binds
to antithrombin to catalyse the inactivation of serine
proteases involved in the coagulation cascade [8]. However,
binding to other plasma proteins also leads to unpredictable
pharmacokinetics and pharmacodynamics, necessitating
close biological monitoring and regular dose adjustments,
and may induce side effects including heparin-induced
thrombocytopenia (HIT) [8]. LMWHs, which are also
administered parenterally as weight-based doses, have a
longer half-life than UFH and are more specific for anti-
thrombin, making them more predictable and associated
with fewer non-haemorrhagic side effects [8]. As a result,
LMWHs have largely replaced UFH, except in certain
circumstances such as in patients with severe renal im-
pairment [creatinine clearance (CrCl) < 30 ml/min], in
which UFH is preferred because it does not accumulate
in patients with compromised renal function (Table 1)
[7]. In the randomised COLUMBUS study, which included
more than 1,000 patients, LMWH (sodium reviparin)
given as treatment for symptomatic VTE for 12 weeks
in combination with VKA was as effective as UFH/VKAE [3,7]
Grade of recommendation/
level of evidence
do not have a high risk of bleeding) 2C (ACCP)/1A (ESC)
1A (ESC)
roxaban* 1B (ACCP)/1A (ESC)
2B/C (ACCP)/1A (ESC)
2B/C (ACCP)/1A (ESC)
d those with severe renal dysfunction,
.5 times the normal range
1C (ESC)
ndaparinux should continue for at
d as soon as possible
1B (ACCP)/1A (ESC)
d after achieving target INR 1B (ACCP)/1C (ESC)
ACCP American College of Chest Physicians, aPTT activated partial
sed ratio, i.v. intravenous, LMWH low molecular weight heparin, PE pulmonary
.
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difference of 0.4 percentage points indicating equiva-
lence by the pre-defined criteria), with no difference in
major bleeding (3.1% vs. 2.3%; P = 0.63) or mortality
(7.1% vs. 7.6%; P = 0.89) [9].
The parenteral indirect factor Xa inhibitor fondaparinux
is a synthetic pentasaccharide that is more specific for anti-
thrombin than LMWH and has a longer half-life. It does
not require routine monitoring and is not associated with a
risk of HIT [8]. In a randomised phase III study in patients
with symptomatic PE, fondaparinux was non-inferior to
UFH for prevention of recurrent VTE when both were
given for initial anticoagulation before transition to a VKA
[3.8% incidence of VTE recurrence at 3 months with
fondaparinux vs. 5.0% with UFH; absolute difference
−1.2% (95% confidence interval −3.0% to 0.5%)]; the inci-
dence of major bleeding was similar for both treatments
(1.3% vs. 1.1%, respectively) [10]. A similarly designed
study including patients with DVT reported equivalent
outcomes between fondaparinux and enoxaparin for effi-
cacy [3.9% incidence of recurrent VTE at 3 months vs.
4.1%, respectively; absolute difference −0.15% (95% confi-
dence interval −1.8% to 1.5%)] and major bleeding (1.1%
vs. 1.2%, respectively) [11].
Initial parenteral anticoagulation provides a swift onset
of action, which is important in acute thrombosis treat-
ment. On the other hand, a potential for overdose exists
owing to the long half-lives of LMWH and fondaparinux,
and although protamine sulphate is able to partially neu-
tralise LMWH, no reversal agent exists for fondaparinux
[4]. For longer term prevention of recurrent thrombosis,
oral VKAs have traditionally been prescribed to patients
when they leave hospital. VKAs do not induce HIT, but
they are associated with various other problems. These
include numerous food and drug interactions that lead
to unpredictable pharmacokinetics and pharmacodynamics,
which in turn necessitate regular coagulation monitoring
and repeated dose adjustment [4].
Rivaroxaban and other non-vitamin K antagonist oral
anticoagulants for the treatment of pulmonary embolism
The direct factor Xa inhibitors rivaroxaban, apixaban and
edoxaban, and the direct thrombin inhibitor dabigatran,
have been developed to address the limitations of trad-
itional anticoagulants. They are administered orally, have a
fast onset of action, and their predictable pharmacokinetics
and pharmacodynamics across a broad range of patients
allow for fixed doses without routine coagulation monitor-
ing [4]. Currently, rivaroxaban is the only such agent to be
approved in Europe and the US for the treatment of DVT
and PE and the prevention of recurrent DVT and PE, at
an initial dose of 15 mg twice daily for 3 weeks followed
by 20 mg once daily for an individualised duration of
anticoagulation [5,6].Rivaroxaban was evaluated for the treatment of PE in the
phase III EINSTEIN PE study (Table 2), which was an
open-label, non-inferiority trial comparing oral rivaroxaban
(15 mg twice daily for 3 weeks, then 20 mg once daily) with
standard subcutaneous enoxaparin (1 mg/kg) twice daily
overlapping with a VKA for the treatment of symptomatic
PE (with or without DVT) [12]. Treatment continued for
3, 6 or 12 months based on each patient’s benefit-risk
profile, local standards and the investigator’s clinical
judgement [12]. A parallel study in patients with DVT
(EINSTEIN DVT), which had the same design but
recruited patients with symptomatic acute proximal
DVT (without PE), was also conducted (Table 2) [13]. The
rationale for conducting separate DVT and PE studies, a
unique approach among trials of non-VKA OACs, was
the distinct nature of these conditions in terms of clinical
management and expected patient outcomes. Consid-
ering that DVT is more common [14], a study includ-
ing both conditions could be insufficiently powered
to confirm efficacy for PE. The two-stage rivaroxaban
dosing regimen was chosen after phase II dose-finding
studies showed an improvement in asymptomatic
thrombotic burden with twice-daily dosing in the acute
phase of treatment but a better bleeding profile with
once-daily dosing [15,16]. Given the potential for early
recurrent thrombosis [17,18], this regimen maintains
intensive anticoagulation in the acute phase and a bal-
ance between effective anticoagulation and bleeding
risk thereafter [19].
In EINSTEIN PE (n = 4,832), approximately one-
quarter of patients with PE had concomitant DVT and
approximately 65% had unprovoked thromboses [12].
Approximately 12% of patients in EINSTEIN PE were
admitted to intensive care and approximately 24%
had anatomically extensive PE [12]. In EINSTEIN PE,
rivaroxaban was non-inferior to enoxaparin/VKA for
the primary efficacy endpoint of recurrent, symptomatic
VTE, with incidences of 2.1% versus 1.8%, respectively
(P = 0.003 for non-inferiority; Figure 1A) [12]. The princi-
pal safety outcome, major plus non-major clinically rele-
vant bleeding, occurred with a similar frequency in both
study arms (10.3% vs. 11.4%, respectively; P = 0.23) [12].
There was no difference in the incidence of recurrent
PE (32 vs. 27 cases) or death during the intended treatment
period (2.4% vs. 2.1%). Significantly, in EINSTEIN PE,
major bleeding, including intracranial and critical-site
bleeding, was halved with rivaroxaban (1.1% vs. 2.2%;
P = 0.003; Figure 1B) [12]. In EINSTEIN DVT (n = 3,449),
rivaroxaban was also non-inferior to enoxaparin/VKA
(2.1% vs. 3.0%; P < 0.001 for non-inferiority) with a similar
incidence of clinically relevant bleeding between the treat-
ment arms (8.1% vs. 8.1%; P = 0.77) [13].
Randomised, phase III acute treatment trials of apixaban,
edoxaban and dabigatran have not assessed DVT and PE
Table 2 Principal outcomes of phase III studies of non-VKA OACs for acute VTE treatment
Study name Interventions Patients Treatment
duration
Primary efficacy outcome Bleeding outcomes
EINSTEIN PE [12] Oral rivaroxaban 15 mg bid for
3 weeks then 20 mg od vs.
enoxaparin s.c. 1.0 mg/kg bid
for ≥ 5 days plus VKA started
≤ 48 h after randomisation
≥ 18 years with confirmed
acute symptomatic PE





2.1% vs. 1.8% (P = 0.003 for
non-inferiority)
Major or non-major clinically
relevant bleeding: 10.3% vs.
11.4% (P = 0.23)
Major bleeding: 1.1% vs. 2.2%
(P = 0.003)







2.1% vs. 3.0% (P < 0.001 for
non-inferiority)
Major and non-major clinically
relevant bleeding: 8.1% vs.
8.1% (P = 0.77)
Major bleeding: 0.8% vs. 1.2%
(P = 0.21)
RE-COVER [20] Parenteral anticoagulant
indication then oral
dabigatran etexilate 150 mg
bid vs. oral warfarin
(INR 2.0-3.0) od
≥ 18 years with acute,
symptomatic VTE
(n = 2,564)
6 months Symptomatic VTE or
VTE-related death: 2.4%
vs. 2.1% (P < 0.001 for
non-inferiority)
Major or non-major clinically
relevant bleeding: 5.6% vs.
8.8% (P = 0.002)
Major bleeding: 1.6% vs. 1.9%
(HR = 0.82; 95% CI 0.45-1.48)
RE-COVER II [21] As for RE-COVER ≥ 18 years with acute,
symptomatic VTE
(n = 2,568)
6 months Symptomatic VTE or
VTE-related death: 2.4%
vs. 2.2% (P < 0.0001 for
non-inferiority)
Any bleeding: 200 vs. 285
patients (HR = 0.67;
95% CI 0.56-0.81)
Major bleeding: 15 vs. 22
patients (HR = 0.69;
95% CI 0.36-1.32)
bid Twice daily, CI, Confidence interval; DVT, Deep vein thrombosis; HR, Hazard ratio; OAC, Oral anticoagulant; od, Once daily; PE, Pulmonary embolism;
s.c., Subcutaneous; VKA, Vitamin K antagonist, VTE, Venous thromboembolism.
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going but two studies – RE-COVER and RE-COVER II –
comparing dabigatran etexilate 150 mg twice daily with
warfarin for the 6-month treatment of acute, symptomatic
VTE have been completed (Table 2) [20,21]. In contrast
with the EINSTEIN trials, which used a single-drug ap-
proach from the start, patients in both study arms received
parenteral anticoagulant induction. In both trials, which
mostly enrolled patients with DVT, the two study arms
were equally efficacious. In RE-COVER, the incidence of
recurrent VTE or VTE-related death was 2.4% compared
with 2.1% with warfarin (P < 0.001 for non-inferiority;
Figure 2A), whereas in RE-COVER II, the same endpoint
was associated with incidences of 2.4% and 2.2%, respect-
ively (P < 0.0001 for non-inferiority). Rates of any bleeding
and major bleeding were similar between the study arms
in both RE-COVER (Figure 2B) and RE-COVER II
[20,21]. A meta-analysis of published phase II and III
studies found that, overall, the non-VKA OACs had
equivalent efficacy in terms of preventing VTE recurrence
compared with VKAs, but rivaroxaban was the only agent
to significantly reduce the risk of major bleeding compared
with standard care [22].
Considerations for clinical practice in the emergency
department
With a rapid onset of action, parenteral agents represent
the routine choice for initial anticoagulation, but non-VKA
OACs also show promise in this setting. Rivaroxaban isa specific factor Xa-targeting anticoagulant that provides a
comparable speed of onset to enoxaparin [5,23], but
without the risk of heparin-induced side effects [4]. Unlike
the indirect factor Xa inhibitor fondaparinux, rivaro-
xaban is administered orally, binds directly to factor Xa
without the need for antithrombin [24], and inhibits free,
prothrombinase-associated and clot-associated factor Xa
[25]. As the only non-VKA OAC currently approved for
the treatment of DVT and PE, the following observations
apply specifically to rivaroxaban, but some may also be
relevant to non-VKA OACs as a class.
Overall, the EINSTEIN trials indicate that the risk of
bleeding is similar between single-agent rivaroxaban and
dual-drug LMWH/VKA. In EINSTEIN PE, there was no
difference in the incidence of clinically relevant bleeding
between the treatment arms in the acute phase of treat-
ment (the first 21 days during which rivaroxaban was given
at 15 mg twice daily), and, overall, major bleeding episodes
were 50% less frequent with rivaroxaban [12]. Nevertheless,
all anticoagulants confer a risk of bleeding, and it is import-
ant to pay attention to any clinical sign of bleeding. If
appropriate, laboratory testing of haemoglobin/haematocrit
and comparison with baseline values could indicate possible
occult bleeding [5,26]. Anticoagulated patients who are at
increased risk of bleeding, such as those with current or
historical bleeding disorders, arterial hypertension, gastro-
intestinal ulcerations, vascular abnormalities or recent cen-
tral nervous system trauma, should be monitored carefully
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Figure 1 Kaplan-Meier curves for the principal efficacy and major bleeding outcomes in EINSTEIN PE. Incidences of (A) recurrent,
symptomatic venous thromboembolism and (B) major bleeding with rivaroxaban versus enoxaparin/vitamin K antagonist [12]. From The New
England Journal of Medicine: The EINSTEIN-PE Investigators, “Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary Embolism”, volume 366,
pages 1287–1297. Copyright © 2012, Massachusetts Medical Society. Reprinted with permission from Massachusetts Medical Society.
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should not be given to haemodynamically unstable patients,
those who require pulmonary embolectomy or those
receiving fibrinolytic agents [5,26].
Rivaroxaban is contraindicated in patients with active
bleeding of clinical significance or a relevant likelihood
of such bleeding caused by hepatic disease associated
with coagulopathy, including cirrhotic patients classified
as Child-Pugh B or C [5]. Approximately one-third of the
rivaroxaban dose is excreted renally as unchanged drug
and a further third is metabolised to inactive metabolites
and then excreted renally [27,28]. No dose adjustment is
generally required in patients with reduced renal function
in the DVT/PE treatment setting, although caution
should be applied in patients with CrCl 15–29 ml/min [5].
It should be noted that patients with CrCl <30 ml/min were
excluded from the EINSTEIN studies [12,13]. Rivaroxaban
is not recommended for patients with CrCl <15 ml/min,
prosthetic heart valves or immediately life-threatening PErequiring thrombolysis or surgery (these patients were ex-
cluded from EINSTEIN PE). Only limited data are available
on rivaroxaban use in cancer patients, who are generally at
increased risk of both VTE and bleeding [7], but outcomes
for rivaroxaban in the EINSTEIN trials for those patients
with active cancer were generally consistent with results for
the overall populations [12,13].
Concomitant administration of rivaroxaban with strong
competitive inhibitors of cytochrome P450 3A4 and
P-glycoprotein (P-gp) – namely azole-antimycotics or
HIV protease inhibitors, including ritonavir – should
be avoided [5,27]. Caution should be exercised when
giving rivaroxaban to patients with moderate renal
impairment (CrCl 30–49 ml/min) who are taking co-
medications that could increase the risk of bleeding,
such as antiplatelet agents, or could lead to a poten-
tial increase in rivaroxaban plasma concentrations
(strong inhibitors of cytochrome P450 3A4 or P-gp,
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Figure 2 Kaplan-Meier curves for the principal efficacy and bleeding outcomes in the RE-COVER study. Incidences of (A) recurrent,
symptomatic venous thromboembolism or related death and (B) major bleeding and any bleeding with dabigatran versus warfarin [20]. From
The New England Journal of Medicine: Schulman et al., “Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism”,
volume 361, pages 2342–2352. Copyright © 2009, Massachusetts Medical Society. Reprinted with permission from Massachusetts Medical Society.
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inadequate level of anticoagulation [5,27]. Co-administration
of rivaroxaban with other anticoagulants is contraindi-
cated unless switching to or from rivaroxaban, and use
of rivaroxaban in combination with dronedarone should
be avoided [5]. Some of these issues can be managed
using clinical judgement or an alternative agent. However, asubstantial proportion of patients are likely to be suitable
for rivaroxaban because it has shown predictable properties
regardless of demographic factors [29-33].
Because rivaroxaban has a relatively short half-life
(5–13 h for a 10-mg dose) [5,34], reversal of anticoagulation
should not normally be required with rivaroxaban. There is
currently no specific antidote to rivaroxaban [35], although
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case of recent overdose. Nevertheless, administration of
up to 600 mg rivaroxaban has been reported without
an increase in bleeding [5]. In the case of bleeding
complications, rivaroxaban should be discontinued or
delayed. Symptomatic treatment, such as mechanical
compression, surgical haemostasis, fluid replacement and
blood products, should be used in an individualised manner
according to the nature and location of the bleeding. If
these measures do not control bleeding, prothrombin
complex concentrate, activated prothrombin complex
concentrate or recombinant factor VIIa can be considered
to reverse the anticoagulant effect, based on limited data
[5,26]. Protamine sulphate and vitamin K infusion will not
affect rivaroxaban activity, and there is no experience
with antifibrinolytic agents or systemic haemostatic drugs.
Rivaroxaban is not dialysable [5].
Rivaroxaban, like the other non-VKA OACs, has predict-
able pharmacokinetic and pharmacodynamic properties
[29-33], and coagulation monitoring is not routinely neces-
sary. A specific calibrated anti-factor Xa chromogenic assay
is the preferred method for measuring rivaroxaban plasma
concentrations (and those of other factor Xa inhibitors) if
required in an emergency [26,36], but if unavailable,
prothrombin time could be used. In the latter case, the
reading must be made in seconds and compared against
known rivaroxaban calibrators and controls; it must not
be converted to an INR [5]. These tests are proposed to
rule out the presence of the drug before acute surgery
or to confirm neutralisation. If emergency surgery is
required, rivaroxaban should ideally be stopped at least
24 h before the intervention, taking into account the
patient’s risk of bleeding against the potential benefit of
surgery [5]. Because of its relatively short half-life [5,34],
rivaroxaban can be stopped closer to the time of surgery
than VKAs and then be restarted when post-surgical
haemostasis is established. Because of the rapid onset of
effect with rivaroxaban, and in contrast to VKAs, there
is no need for LMWH bridging.
The emergency physician may be faced with a patient
with atrial fibrillation, or one who has recently undergone
major orthopaedic surgery, who is taking anticoagulants
but has symptoms suggestive of an acute PE. Poor control
or non-adherence to VKA therapy could increase such a
possibility. There is no official recommendation for this
situation, but if the patient is already receiving rivaroxaban
the logical strategy would be to increase the anticoagulant
dose to an appropriate level for VTE treatment, provided
the patient’s benefit-risk profile for recurrent VTE, atrial
fibrillation-related stroke and bleeding is felt to be in
favour of such an approach. The patient could be receiving
dabigatran, but because dabigatran is not currently indi-
cated for VTE treatment, a transition to an alternative
agent may be necessary in this case. It has been suggestedthat rivaroxaban may be administered concurrently with
acetylsalicylic acid (ASA), provided that the dose of ASA
does not exceed 100 mg per day [37]. However, rivaroxaban
15 mg or 20 mg should not be combined with dual
antiplatelet therapy (ASA plus clopidogrel, ticlopidine,
prasugrel or ticagrelor) [37].
If a patient is receiving a VKA and control is suboptimal,
switching to rivaroxaban for treatment is possible by
discontinuing the VKA and starting rivaroxaban when the
INR is below 2.5 [5]. There are circumstances in which oral
anticoagulation is not possible or adequate in the emer-
gency setting – for example, when the patient is unable to
swallow a capsule or tablet. In this case, initial parenteral
anticoagulation remains appropriate for induction therapy.
It is then possible to switch to rivaroxaban by giving the
first dose at the same time that the next dose of LMWH or
fondaparinux is scheduled [5].Conclusion
Acute PE is a potentially life-threatening event that requires
rapid, effective anticoagulant treatment. Non-VKA OACs,
such as rivaroxaban, offer potential advantages over trad-
itional antithrombotic agents for the treatment of VTE in
many patients, simplifying their management without com-
promising antithrombotic efficacy or safety. Nevertheless,
there are specific circumstances where these agents are not
recommended, and clinical experience will serve to further
define appropriate use.Abbreviations
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